187 related articles for article (PubMed ID: 38486046)
1. Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: a retrospective cohort study.
Wang W; Volkow ND; Berger NA; Davis PB; Kaelber DC; Xu R
Mol Psychiatry; 2024 Mar; ():. PubMed ID: 38486046
[TBL] [Abstract][Full Text] [Related]
2. Association of semaglutide with risk of suicidal ideation in a real-world cohort.
Wang W; Volkow ND; Berger NA; Davis PB; Kaelber DC; Xu R
Nat Med; 2024 Jan; 30(1):168-176. PubMed ID: 38182782
[TBL] [Abstract][Full Text] [Related]
3. Real-World Effectiveness of Once-Weekly Semaglutide From a US Commercially Insured and Medicare Advantage Population.
Visaria J; Uzoigwe C; Swift C; Dang-Tan T; Paprocki Y; Willey VJ
Clin Ther; 2021 May; 43(5):808-821. PubMed ID: 33785221
[TBL] [Abstract][Full Text] [Related]
4. Integrating oral semaglutide into clinical practice in primary care: for whom, when, and how?
Brunton SA; Mosenzon O; Wright EE
Postgrad Med; 2020 Nov; 132(sup2):48-60. PubMed ID: 32815453
[TBL] [Abstract][Full Text] [Related]
5. Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups.
Yale JF; Bodholdt U; Catarig AM; Catrina S; Clark A; Ekberg NR; Erhan U; Holmes P; Knudsen ST; Liutkus J; Sathyapalan T; Schultes B; Rudofsky G
BMJ Open Diabetes Res Care; 2022 Apr; 10(2):. PubMed ID: 35383100
[TBL] [Abstract][Full Text] [Related]
6. Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population.
Wang W; Volkow ND; Berger NA; Davis PB; Kaelber DC; Xu R
Nat Commun; 2024 May; 15(1):4548. PubMed ID: 38806481
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness in Real World of Once Weekly Semaglutide in People with Type 2 Diabetes: Glucagon-Like Peptide Receptor Agonist Naïve or Switchers from Other Glucagon-Like Peptide Receptor Agonists: Results from a Retrospective Observational Study in Umbria.
Di Loreto C; Minarelli V; Nasini G; Norgiolini R; Del Sindaco P
Diabetes Ther; 2022 Mar; 13(3):551-567. PubMed ID: 35230650
[TBL] [Abstract][Full Text] [Related]
8. Semaglutide 2.4-mg injection as a novel approach for chronic weight management.
Kyrillos J
Am J Manag Care; 2022 Dec; 28(15 Suppl):S297-S306. PubMed ID: 36525677
[TBL] [Abstract][Full Text] [Related]
9. Real-world impact of once-weekly subcutaneous semaglutide after 2 years of follow-up: Results from a nationwide observational study in people with type 2 diabetes.
Vilsbøll T; Lindahl CØ; Nielsen NF; Tikkanen CK
Diabetes Obes Metab; 2023 Jun; 25(6):1740-1749. PubMed ID: 36809678
[TBL] [Abstract][Full Text] [Related]
10. Effects of Once-Weekly Semaglutide on Cardiovascular Risk Factors and Metabolic Dysfunction-Associated Steatotic Liver Disease in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study Based on Real-World Data.
Katsuyama H; Hakoshima M; Kaji E; Mino M; Kakazu E; Iida S; Adachi H; Kanto T; Yanai H
Biomedicines; 2024 May; 12(5):. PubMed ID: 38790963
[TBL] [Abstract][Full Text] [Related]
11. Once-weekly subcutaneous semaglutide treatment for persons with type 2 diabetes: Real-world data from a diabetes out-patient clinic.
Hansen KB; Svendstrup M; Lund A; Knop FK; Vilsbøll T; Vestergaard H
Diabet Med; 2021 Oct; 38(10):e14655. PubMed ID: 34291491
[TBL] [Abstract][Full Text] [Related]
12. Adherence and persistence among patients with type 2 diabetes initiating dulaglutide compared with semaglutide and exenatide BCise: 6-month follow-up from US real-world data.
Mody R; Yu M; Nepal B; Konig M; Grabner M
Diabetes Obes Metab; 2021 Jan; 23(1):106-115. PubMed ID: 32945083
[TBL] [Abstract][Full Text] [Related]
13. Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study.
Yang CT; Yang CY; Ou HT; Kuo S
Cardiovasc Diabetol; 2020 Jun; 19(1):83. PubMed ID: 32534570
[TBL] [Abstract][Full Text] [Related]
14. Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide.
Gallwitz B; Giorgino F
Front Endocrinol (Lausanne); 2021; 12():645507. PubMed ID: 34267725
[TBL] [Abstract][Full Text] [Related]
15. Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy.
Wright EE; Aroda VR
Postgrad Med; 2020 Nov; 132(sup2):26-36. PubMed ID: 32815423
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review.
Xie Z; Hu J; Gu H; Li M; Chen J
Front Endocrinol (Lausanne); 2023; 14():1244432. PubMed ID: 37701904
[TBL] [Abstract][Full Text] [Related]
17. Risks of stroke, its subtypes and atrial fibrillation associated with glucagon-like peptide 1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: a real-world population-based cohort study in Hong Kong.
Lui DTW; Tang EHM; Wu T; Au ICH; Lee CH; Woo YC; Tan KCB; Wong CKH
Cardiovasc Diabetol; 2023 Feb; 22(1):40. PubMed ID: 36829226
[TBL] [Abstract][Full Text] [Related]
18. Association of GLP-1 Receptor Agonists and Hepatocellular Carcinoma Incidence and Hepatic Decompensation in Patients With Type 2 Diabetes.
Wang L; Berger NA; Kaelber DC; Xu R
Gastroenterology; 2024 Apr; ():. PubMed ID: 38692395
[TBL] [Abstract][Full Text] [Related]
19. Once-Weekly Semaglutide Use in Type 2 Diabetes: Real-World Data from the SURE Netherlands Observational Study.
Wolffenbuttel BHR; Brugts MP; Catarig AM; Clark A; Kok M; Lieverse AG; van Soest J
Adv Ther; 2023 Mar; 40(3):920-933. PubMed ID: 36542260
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy of treatment with glucagon-like peptide receptor agonists-1 in Asian patients with type 2 diabetes mellitus].
Khamnueva LY; Andreeva LS
Probl Endokrinol (Mosk); 2023 May; 69(2):38-46. PubMed ID: 37448270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]